In our results, we demonstrated that abemaciclib treatment inhibited cell proliferation in three GBM cancer cells including RB-deficient M059K cells, which means abemaciclib inhibits cell growth, possibly in an Rb-independent manner. The gene discussed is RB1; the disease is glioblastoma.